Immupharma (IMM) RNS Announcements

Add to Alert list
Date Time Source Announcement
07 Sep 2023 07:00 AM
RNS
Result of Retail Offer and Director Shareholding
06 Sep 2023 01:53 PM
RNS
Holding(s) in Company
31 Aug 2023 07:02 AM
RNS
WRAP Retail Offer for up to £0.5m
31 Aug 2023 07:01 AM
RNS
Subscription to raise £1.35m; Sharing Agr, RPT
31 Aug 2023 07:00 AM
RNS
Interim results
21 Aug 2023 07:00 AM
RNS
Extension of warrants in Incanthera plc
11 Aug 2023 12:04 PM
RNS
Directorate Change
30 Jun 2023 01:12 PM
RNS
Result of AGM
19 Jun 2023 07:00 AM
RNS
Lupuzor Update
06 Jun 2023 07:00 AM
RNS
IMM RNS Posting of RA and Notice of AGM 30 June 23
18 May 2023 07:00 AM
RNS
Positive Pre-IND meeting with FDA
11 May 2023 07:00 AM
RNS
Final Results
10 May 2023 01:56 PM
RNS
Holding(s) in Company
19 Apr 2023 07:00 AM
RNS
Lupozor Update - FDA confirms Type-C meeting date
12 Apr 2023 07:00 AM
RNS
CIDP P140 Clinical Program Update
27 Mar 2023 07:00 AM
RNS
LupuzorT Update
09 Mar 2023 04:35 PM
RNS
Price Monitoring Extension
06 Mar 2023 07:00 AM
RNS
Collaboration with Orano on ImmuPharma Peptide
06 Feb 2023 07:00 AM
RNS
LupuzorT Update
27 Jan 2023 04:25 PM
RNS
TR-1: Notification of major holdings
04 Jan 2023 05:26 PM
RNS
TR-1: Notification of major holdings
04 Jan 2023 04:40 PM
RNS
Second Price Monitoring Extn
04 Jan 2023 04:35 PM
RNS
Price Monitoring Extension
03 Jan 2023 04:58 PM
RNS
TR-1: Notification of major holdings
22 Dec 2022 07:55 AM
RNS
Grant of Options
22 Dec 2022 07:00 AM
RNS
End of Year Update
22 Nov 2022 03:15 PM
RNS
Holding(s) in Company
14 Nov 2022 04:40 PM
RNS
Second Price Monitoring Extn
14 Nov 2022 04:35 PM
RNS
Price Monitoring Extension
11 Nov 2022 07:31 AM
RNS
Lupuzor Update
11 Oct 2022 04:40 PM
RNS
Second Price Monitoring Extn
11 Oct 2022 04:35 PM
RNS
Price Monitoring Extension
07 Oct 2022 04:44 PM
RNS
Company Secretary Change
30 Sep 2022 07:30 AM
RNS
Lupuzor Update
30 Sep 2022 07:00 AM
RNS
Interim Results or the 6mths Ended 30 June 2022
29 Sep 2022 04:40 PM
RNS
Second Price Monitoring Extn
29 Sep 2022 04:37 PM
RNS
Price Monitoring Extension
14 Sep 2022 10:04 AM
RNS
Written Response received from the FDA
07 Sep 2022 08:25 AM
RNS
Exercise of Options
31 Aug 2022 07:00 AM
RNS
FDA response for Type C Meeting - update
30 Aug 2022 11:29 AM
RNS
Exercise of Options
24 Aug 2022 08:11 AM
RNS
Exercise of Options
17 Aug 2022 06:12 PM
RNS
TR-1 Notification of major holdings
16 Aug 2022 08:03 AM
RNS
Total Voting Rights
11 Aug 2022 07:00 AM
RNS
Result of Broker Option / PDMR Dealings
04 Aug 2022 07:00 AM
RNS
Investor Presentation - Investor Meet Company
03 Aug 2022 04:40 PM
RNS
Second Price Monitoring Extn
03 Aug 2022 04:35 PM
RNS
Price Monitoring Extension
03 Aug 2022 04:33 PM
RNS
Subscription/Placing to raise £1.1m; Broker Option
26 Jul 2022 04:41 PM
RNS
Second Price Monitoring Extn

ImmuPharma is a pharma company headquartered in London with its research R&D team, ImmuPharma Biotech, based in France. 

ImmuPharma listed on AIM under the ticker IMM. 

IMM research strategy is based on two strategic axes: research based on external collaboration aimed at discovering new active ingredients, which has led to the development of our most advanced project in terms of clinical development: P140 an active peptide against the auto-immune disease, Lupus SLE and internal research based on the use of molecular programming technologies, which has notably led to the development of the BioAMB and BioCIN projects.

IMM share price listed in London at 1,190p in 2000. 

UK 100

Latest directors dealings